abcam

ab309938

# Alexa Fluor® 488 Anti-LYPD3 antibody [SP250] - N-terminal

Recombinant | RabMAb

## Key facts

| | |
|---|---|
| **Isotype** | IgG |
| **Host species** | Rabbit |
| **Conjugation** | Alexa Fluor® 488 |
| **Excitation/Emission** | Ex: 495nm, Em: 519nm |
| **Storage buffer** | pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA |
| **Form** | Liquid |
| **Clonality** | Monoclonal |
| **Immunogen** | The exact immunogen used to generate this antibody is proprietary information. |
| **Clone number** | SP250 |
| **Purification technique** | Affinity purification Protein A |

## Reactivity data

## Target Binding Affinity

### Expected

| | |
|---|---|
| **Species** | Human |
| **Dilution info** | Use at an assay dependent concentration. |

| | |
|---|---|
| **Notes** | - |

## Antibody Labelling

### Expected

| | |
|---|---|
| **Species** | Human |
| **Dilution info** | Use at an assay dependent concentration. |
| **Notes** | - |

## Flow Cyt

### Expected

| | |
|---|---|
| **Species** | Human |
| **Dilution info** | Use at an assay dependent concentration. |
| **Notes** | - |

## IHC-P

### Expected

| | |
|---|---|
| **Species** | Human |
| **Dilution info** | Use at an assay dependent concentration. |
| **Notes** | - |

# Target data

See full target information LYPD3

| | |
|---|---|
| **Function** | Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression. |

# Storage

| | |
|---|---|
| **Shipped at conditions** | Blue Ice |
| **Appropriate short-term storage duration** | 1-2 weeks |

| | |
|---|---|
| **Appropriate short-term storage conditions** | +4°C |
| **Appropriate long-term storage conditions** | -20°C |
| **Aliquoting information** | Upon delivery aliquot |
| **Storage information** | Avoid freeze / thaw cycle, Store in the dark |

## Notes

**Patented technology**
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

**How are conjugated primary antibodies validated?**
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

**What are the advantages of a recombinant monoclonal antibody?**
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

## Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

| | |
|---|---|
| **Activity summary** | LYPD3 also known as C4.4A is a glycosylphosphatidylinositol (GPI)-anchored protein with a molecular weight of approximately 40 kDa. It belongs to the Ly6/PLAUR domain family. This protein is mainly expressed in stratified epithelia and also found in some other tissues. LYPD3 shows higher expression levels in certain cancer cell types indicating its role in tumorigenesis. |
| **Biological function summary** | LYPD3 functions in cellular adhesion and migration processes. It interacts with extracellular matrix components facilitating the movement and positioning of cells. It acts as a part of a protein complex that is important for cell communication and tissue organization. Its high expression in some cancer types suggests its involvement in processes that drive cancer progression including metastasis. |
| **Pathways** | LYPD3 participates in key signaling cascades including integrin-mediated pathways. These pathways are important for mediating cell-matrix interactions |

| | |
|---|---|
| | and influence cell movement and survival. LYPD3 has known interactions with integrin proteins suggesting a collaborative role that modulates cell adhesion dynamics. These interactions make it an important player in cell migration and invasion processes that are pivotal for normal physiological events and pathological conditions. |
| **Associated diseases and disorders** | LYPD3 shows significant involvement in cancers such as squamous cell carcinoma and prostate cancer. The protein aids the metastatic spread of these cancers by promoting cell migration and invasion. It has been associated with other proteins like laminin which supports cancer cell detachment and dissemination. Understanding LYPD3's role in cancer biology helps in identifying therapeutic targets for impeding cancer progression. |

## Product promise

**Tested**

We have tested this species and application combination and it works. It is covered by our product promise.

**Expected**

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

**Predicted**

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

**Not recommended**

We do not recommend this combination. It is not covered by our product promise.

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.